Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
03 2020
Historique:
received: 04 09 2019
revised: 24 10 2019
accepted: 03 11 2019
pubmed: 15 11 2019
medline: 24 6 2021
entrez: 15 11 2019
Statut: ppublish

Résumé

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects.

Identifiants

pubmed: 31726205
pii: S1083-8791(19)30743-8
doi: 10.1016/j.bbmt.2019.11.003
pmc: PMC7367505
mid: NIHMS1600729
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

553-561

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL150232
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

N Engl J Med. 2017 Mar 9;376(10):947-956
pubmed: 28273021
Lancet Oncol. 2017 Jan;18(1):e30-e38
pubmed: 28049575
J Vasc Surg. 2017 Jun;65(6):1625-1635
pubmed: 28216362
Haematologica. 2019 May;104(5):1084-1092
pubmed: 30514795
Med Pediatr Oncol. 2002 Jul;39(1):2-1; discussion 2
pubmed: 12116072
Biol Blood Marrow Transplant. 2012 May;18(5):708-15
pubmed: 21906576
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
pubmed: 23906634
Blood Adv. 2017 Aug 22;1(19):1617-1627
pubmed: 29296802
J Cancer Surviv. 2016 Oct;10(5):814-31
pubmed: 26920873
Am J Hematol. 2011 Jan;86(1):116-20
pubmed: 21061308
J Cancer Surviv. 2011 Sep;5(3):292-304
pubmed: 21544671
Best Pract Res Clin Haematol. 2008 Jun;21(2):193-204
pubmed: 18503986
Pediatr Blood Cancer. 2018 Nov;65(11):e27364
pubmed: 30024087
Blood. 2010 Oct 28;116(17):3129-39; quiz 3377
pubmed: 20656930
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5
pubmed: 20036337
Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71
pubmed: 22178693
PLoS One. 2013 Apr 18;8(4):e61586
pubmed: 23637862
Adolesc Health Med Ther. 2015 Aug 18;6:141-8
pubmed: 26316835
Biol Blood Marrow Transplant. 2015 Feb;21(2):225-32
pubmed: 24999225
Blood Adv. 2019 Feb 12;3(3):397-405
pubmed: 30728138
J Am Coll Cardiol. 2018 Apr 24;71(16):1768-1777
pubmed: 29673467
Am J Clin Oncol. 2018 Oct;41(10):1024-1027
pubmed: 29028642
PLoS One. 2018 Jun 15;13(6):e0198075
pubmed: 29906287
Biol Blood Marrow Transplant. 2016 Apr;22(4):731-743
pubmed: 26746819
Haematologica. 2017 Apr;102(4):614-625
pubmed: 28232372
Biol Blood Marrow Transplant. 2016 Jul;22(7):1319-1323
pubmed: 27013013
J Int AIDS Soc. 2017 Jul 17;20(1):21737
pubmed: 28715158
PLoS One. 2016 Mar 07;11(3):e0150816
pubmed: 26950470
J Psychosoc Oncol. 2011;29(4):394-414
pubmed: 21966725
Biol Blood Marrow Transplant. 2018 Jan;24(1):4-12
pubmed: 28963077
Bone Marrow Transplant. 2016 Feb;51(2):176-81
pubmed: 26642340
Biol Blood Marrow Transplant. 2017 Feb;23(2):184-192
pubmed: 27818318
Front Oncol. 2013 Apr 08;3:75
pubmed: 23580328

Auteurs

David Buchbinder (D)

Division of Pediatric Hematology, Children's Hospital of Orange County, Orange, California. Electronic address: dbuchbinder@choc.org.

Ruta Brazauskas (R)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Khalid Bo-Subait (K)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Karen Ballen (K)

Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.

Susan Parsons (S)

The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

Tami John (T)

Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas.

Theresa Hahn (T)

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

Akshay Sharma (A)

Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee.

Amir Steinberg (A)

Division of Hematology and Oncology, Mount Sinai Hospital, New York, New York.

Anita D'Souza (A)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Anita J Kumar (AJ)

The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.

Ayami Yoshimi (A)

Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.

Baldeep Wirk (B)

Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, Washington.

Bronwen Shaw (B)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

César Freytes (C)

Texas Transplant Institute, San Antonio, Texas.

Charles LeMaistre (C)

Hematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee.

Christopher Bredeson (C)

Ottawa Hospital Blood and Marrow Transplant Program and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Christopher Dandoy (C)

UC Department of Pediatrics and Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

David Almaguer (D)

Hematology Service at the University Hospital in Monterrey Mexico, and the Stem cell Transplantation Program, Hospital Universitario Dr José E. González, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.

David I Marks (DI)

Adult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.

David Szwajcer (D)

Department of Hematology/Oncology, CancerCare Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada.

Gregory Hale (G)

Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St Petersburg, Florida.

Harry Schouten (H)

Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands.

Hasan Hashem (H)

Division of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.

Hélène Schoemans (H)

Hematology department and Bone marrow transplant unit, University Hospital Leuven and KU Leuven, Leuven, Belgium.

Hemant S Murthy (HS)

Mayo Clinic Florida, Jacksonville, Florida.

Hillard M Lazarus (HM)

Department of Medicine, Case Western Reserve University, Cleveland, Ohio.

Jan Cerny (J)

Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.

Jason Tay (J)

Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

Jean A Yared (JA)

Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.

Kehinde Adekola (K)

Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Kirk R Schultz (KR)

Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.

Leslie Lehmann (L)

Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts.

Linda Burns (L)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.

Mahmoud Aljurf (M)

Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.

Miguel Angel Diaz (MA)

Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.

Navneet Majhail (N)

Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Nosha Farhadfar (N)

Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, Florida.

Rammurti Kamble (R)

Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.

Richard Olsson (R)

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.

Raquel Schears (R)

Department of Emergency Medicine, University of Central Florida, Orlando, Florida.

Sachiko Seo (S)

Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.

Sara Beattie (S)

Department of Psychosocial Oncology and Rehabilitation, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

Saurabh Chhabra (S)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Bipin N Savani (BN)

Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Sherif Badawy (S)

Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Siddhartha Ganguly (S)

Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.

Stefan Ciurea (S)

MD Anderson Cancer Center, Houston, Texas.

Susana Marino (S)

Department of Pathology, University of Chicago Medicine, Chicago, Illinois.

Usama Gergis (U)

Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.

Yachiyo Kuwatsuka (Y)

Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Yoshihiro Inamoto (Y)

Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Nandita Khera (N)

Department of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona.

Shahrukh Hashmi (S)

Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia; Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

William Wood (W)

Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

Wael Saber (W)

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH